HistoSonics, a company developing ultrasound-powered technology to fight cancer, announced Monday that it had closed on a $54 million Series C round to prepare for commercialization of its medical device.
HistoSonics' technology uses sound energy to liquefy and destroy cancerous tumors without affecting surrounding tissue. Branded as Robotically Assisted Sonic Therapy (RAST), the technology, called histotripsy, combines advanced robotics, imaging and sensor technology to exploit microscopic air…
